Clinical Trial Update: Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of ASP9521 in castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ASP9521 (ASP9521)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Castrate Resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED